Mesenteric Vasoconstriction and Hindquarters Vasodilatation Accompany the Pressor Actions of Exendin-4 in Conscious Rats

No abstract is available for this paper.

• Publication year

  2006

• Venue

  Journal of Pharmacology and Experimental Therapeutics

• Publication date

  2006-02-01

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1124/JPET.105.093104PMID 16221740
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Glucagon-like peptide-1 relaxes rat conduit arteries via an endothelium-independent mechanism.

  2005cited by this paper
• The selectivity of β‐adrenoceptor antagonists at the human β1, β2 and β3 adrenoceptors

  2005cited by this paper
• Peptide YY administration into the posterior hypothalamic nucleus of the rat evokes cardiovascular changes by non-adrenergic, non-cholinergic mechanisms.

  2005cited by this paper
• The selectivity of beta-adrenoceptor antagonists at the human beta1, beta2 and beta3 adrenoceptors.

  2005cited by this paper
• Electrophysiologic effects of salbutamol, a beta2-selective agonist.

  2004cited by this paper
• Glucagon-like peptide-1: the basis of a new class of treatment for type 2 diabetes.

  2004cited by this paper
• Acute Cardiovascular Effects of Sibutramine in Conscious Rats

  2004cited by this paper
• Electrophysiologic Effects of Salbutamol, a β2‐Selective Agonist

  2004cited by this paper
• Effects of intracerebroventricularly injected glucagon-like peptide-1 on cardiovascular parameters; role of central cholinergic system and vasopressin.

  2004cited by this paper
• Exendin-4, a GLP-1 receptor agonist, stimulates pituitary-adrenocortical axis in the rat: Investigations into the mechanism(s) underlying Ex4 effect.

  2003cited by this paper
• Glucagon-Like Peptide-1-Responsive Catecholamine Neurons in the Area Postrema Link Peripheral Glucagon-Like Peptide-1 with Central Autonomic Control Sites

  2003cited by this paper
• Effects of glucagon-like peptide-1(7-36) amide on neurohypophysial and cardiovascular functions under hypo- or normotensive hypovolaemia in the rat.

  2002cited by this paper
• Local, exendin-(9-39)-insensitive, site of action of GLP-1 in canine ileum.

  2002cited by this paper
• Influence of the CB1 receptor antagonist, AM 251, on the regional haemodynamic effects of WIN‐55212‐2 or HU 210 in conscious rats

  2002cited by this paper
• Glucagon-like peptide-1 receptor stimulation increases blood pressure and heart rate and activates autonomic regulatory neurons.

  2002cited by this paper
• Vasorelaxant effect of glucagon-like peptide-(7-36)amide and amylin on the pulmonary circulation of the rat.

  2001cited by this paper
• Glucagon-Like Peptide-1 Increases cAMP but Fails to Augment Contraction in Adult Rat Cardiac Myocytes

  2001cited by this paper
• Minireview: the glucagon-like peptides.

  2001cited by this paper
• Glucagon-like peptide 1 has a physiological role in the control of postprandial glucose in humans: studies with the antagonist exendin 9-39.

  1999cited by this paper
• Neural contribution to the effect of glucagon-like peptide-1-(7-36) amide on arterial blood pressure in rats.

  1999cited by this paper
• In vivo demonstration of alpha-adrenoceptor-mediated positive inotropy in pithed rats: evidence that noradrenaline does not stimulate myocardial alpha-adrenoceptors.

  1999cited by this paper
• The glucagon-like peptides.

  1999cited by this paper
• Subcutaneous glucagon-like peptide-1 (7-36) amide is insulinotropic and can cause hypoglycaemia in fasted healthy subjects.

  1998cited by this paper
• Interactions of exendin-(9-39) with the effects of glucagon-like peptide-1-(7-36) amide and of exendin-4 on arterial blood pressure and heart rate in rats.

  1996cited by this paper
• Regional haemodynamic responses to pituitary adenylate cyclase‐activating polypeptide and vasoactive intestinal polypeptide in conscious rats

  1994cited by this paper
• Changes in arterial blood pressure and heart rate induced by glucagon-like peptide-1-(7-36) amide in rats.

  1994cited by this paper
• Differential regional haemodynamic effects of the non-peptide angiotensin II antagonist, DuP 753, in water-replete and water-deprived Brattleboro rats.

  1991cited by this paper
• Salmeterol, a novel, long‐acting β2‐adrenoceptor agonist: characterization of pharmacological activity in vitro and in vivo

  1991cited by this paper
• Regional hemodynamic changes following hypovolemia in conscious rats.

  1989cited by this paper
• Regional haemodynamic effects of neuropeptide Y, vasopressin and angiotensin II in conscious, unrestrained, Long Evans and Brattleboro rats.

  1988cited by this paper
• Friedman and Quade tests: BASIC computer program to perform nonparametric two-way analysis of variance and multiple comparisons on ranks of several related samples.

  1987cited by this paper
• The Pharmacology of a β2‐Selective Adrenoceptor Antagonist (ICI 118,551)

  1983cited by this paper
• The pharmacology of a beta 2-selective adrenoceptor antagonist (ICI 118,551).

  1983cited by this paper

• Arterial responses to infusion of Glucagon-like Peptide-1 in humans: A randomized trial study.

  2022cites this paper
• The Effects of Glucagon-Like Peptide-1 Receptor Agonists and Dipeptydilpeptidase-4 Inhibitors on Blood Pressure and Cardiovascular Complications in Diabetes

  2021cites this paper
• Effects of Acute GLP-1 Infusion on Pulmonary and Systemic Hemodynamics in Patients With Heart Failure: A Pilot Study.

  2019cites this paper
• GLP-1 analog liraglutide-induced cardiac dysfunction due to energetic starvation in heart failure with non-diabetic dilated cardiomyopathy

  2019cites this paper
• Glucagon-like peptide 1 (GLP-1)

  2019cites this paper
• Cardiovascular, renal and liver protection with novel antidiabetic agents beyond blood glucose lowering in type 2 diabetes: consensus article from the European Society of Hypertension Working Group on Obesity, Diabetes and the High-risk Patient.

  2019cites this paper
• Different mechanisms involved in liraglutide and glucagon‐like peptide‐1 vasodilatation in rat mesenteric small arteries

  2018cites this paper
• Effects on repetitive 24-hour ambulatory blood pressure in subjects with type II diabetes randomized to liraglutide or glimepiride treatment both in combination with metformin: a randomized open parallel-group study.

  2018cites this paper
• The regulatory role of DPP4 in atherosclerotic disease

  2017cites this paper
• Gastrointestinal and Cardiovascular Effects of Incretin-Based Therapies: Friend or Foe?

  2017cites this paper
• GLP-1 Agonists and Blood Pressure: A Review of the Evidence

  2016cites this paper
• Cardiovascular safety of dipeptidyl peptidase-4 inhibitors: recent evidence on heart failure.

  2016cites this paper
• Effects of Glucagon-Like Peptide-1 on Arteriovenous Fistula Remodelling and Vascular Smooth Muscle Cell Phenotype Switching in Diabetic Rats

  2016cites this paper
• Exendin-4 Prevents Vascular Smooth Muscle Cell Proliferation and Migration by Angiotensin II via the Inhibition of ERK1/2 and JNK Signaling Pathways

  2015cites this paper
• Cardiovascular, renal and gastrointestinal effects of incretin-based therapies: an acute and 12-week randomised, double-blind, placebo-controlled, mechanistic intervention trial in type 2 diabetes

  2015cites this paper
• Endogenous Glucagon-Like Peptide-1 Reduces Drinking Behavior and Is Differentially Engaged by Water and Food Intakes in Rats

  2014cites this paper
• Glucagon-like peptide-1 (7–36) but not (9–36) augments cardiac output during myocardial ischemia via a Frank–Starling mechanism

  2014cites this paper
• Optimising cardioprotection during myocardial ischaemia: targeting potential intracellular pathways with glucagon-like peptide-1

  2014cites this paper
• GLUCAGON LIKE PEPTIDE-1 ( 7 – 36 ) BUT NOT ( 9 – 36 ) AUGMENTS CARDIAC OUTPUT DURING MYOCARDIAL ISCHEMIA VIA AFRANK-STARLING MECHANISM

  2014cites this paper
• Cardiovascular and hemodynamic effects of glucagon-like peptide-1

  2014cites this paper
• Exendin-4 ameliorates cardiac ischemia/reperfusion injury via caveolae and caveolins-3

  2014cites this paper
• Role of the Glucagon and Glucagon-like Peptides in Pancreatic Beta Cell and Cardiovascular Function

  2014cites this paper
• Glucagon‐Like Peptide‐1 Receptor Agonist Administration Suppresses Both Water and Saline Intake in Rats

  2013cites this paper
• Exendin-4, a glucagon-like peptide-1 receptor agonist, attenuates neointimal hyperplasia after vascular injury.

  2013cites this paper
• Role of GLP-1 receptor agonists in endothelial function

  2012cites this paper
• Cardiovascular biology of the incretin system.

  2012influential citation
• GLP-1, exendin-4 and C-peptide regulate pancreatic islet microcirculation, insulin secretion and glucose tolerance in rats.

  2012cites this paper
• Incretins in type 2 diabetes mellitus: cardiovascular and anti-atherogenic effects beyond glucose lowering.

  2012cites this paper
• Effects of intravenous exenatide in type 2 diabetic patients with congestive heart failure: a double-blind, randomised controlled clinical trial of efficacy and safety

  2012cites this paper
• Investigation of the haemodynamic effects of exenatide in healthy male subjects.

  2012cites this paper
• Effects of incretins on blood pressure: A promising therapy for type 2 diabetes mellitus with hypertension

  2012cites this paper
• GLP‐1 Biology, Signaling Mechanisms, Physiology, and Clinical Studies

  2011cites this paper
• Glucagon-like peptide-1 receptor agonists suppress water intake independent of effects on food intake.

  2011cites this paper
• water intake independent of effects on food intake Glucagon-like peptide-1 receptor agonists suppress

  2011cites this paper
• The diabetic cardiomyopathy

  2011cites this paper
• Glucagon-like peptide-1 and the exenatide analogue AC3174 improve cardiac function, cardiac remodeling, and survival in rats with chronic heart failure

  2010cites this paper
• Studies on Incretins and Cardiovascular Function

  2010influential citation
• Exendin-4 increases blood glucose levels acutely in rats by activation of the sympathetic nervous system.

  2010cites this paper
• The exenatide analogue AC3174 attenuates hypertension, insulin resistance, and renal dysfunction in Dahl salt-sensitive rats

  2010cites this paper
• Possible involvement of GLP‐1(9–36) in the regional haemodynamic effects of GLP‐1(7–36) in conscious rats

  2010cites this paper
• Insulin Inhibits and Oral Sucrose Increases Neointimal Growth after Arterial Injury in Rats

  2010cites this paper
• GLP-1(7-36)-amide and Exendin-4 stimulate the HPA axis in rodents and humans.

  2010cites this paper
• Glucagon-like peptide 1--a cardiologic dimension.

  2010influential citation
• Pleiotropic actions of the incretin hormones.

  2010cites this paper
• Studies on Incretins and Cardiovascular Function

  2010cites this paper
• Hypoglycemic pharmacological treatment of type 2 diabetes: targeting the endothelium.

  2009cites this paper
• Endothelial dysfunction induced by triglycerides is not restored by exenatide in rat conduit arteries ex vivo.

  2009cites this paper
• Exenatide Improves Hypertension in a Rat Model of the Metabolic Syndrome

  2009influential citation
• Emerging cardiovascular actions of the incretin hormone glucagon‐like peptide‐1: potential therapeutic benefits beyond glycaemic control?

  2009influential citation
• Glucagon-Induced Vasospasm of Hepatic Artery Branches During Visceral Angiography

  2008cites this paper
• Future perspectives on glucagon-like peptide-1, diabetes and cardiovascular risk.

  2008cites this paper
• The Potential Beneficial Role of Glucagon-like Peptide-1 in Endothelial Dysfunction and Heart Failure Associated with Insulin Resistance

  2008cites this paper
• Autonomic nervous system‐dependent and ‐independent cardiovascular effects of exendin‐4 infusion in conscious rats

  2008cites this paper
• DPP4 inhibitors for diabetes--what next?

  2008cites this paper
• Effects of Glucagon-Like Peptide-1 and Long-Acting Analogues on Cardiovascular and Metabolic Function

  2007cites this paper
• Utilisation d'exendines et d'agonistes d'exendines et d'agonistes des récepteurs du glp-1 pour modifier la concentration de fibrinogène

  2007cites this paper
• Effects of nitric oxide synthase inhibition with or without cyclooxygenase‐2 inhibition on resting haemodynamics and responses to exendin‐4

  2006cites this paper